Randomization in phase II trials: No exemption based on sample size

Documenti analoghi

• Investigating started sample size, completed sample size and drop‐out rate in 10 252 phase III clinical trials: Insights from ClinicalTrials.gov
  di: Henian Chen, et al.
  Pubblicazione: (2025)
• The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
  di: Elise Le Flohic, et al.
  Pubblicazione: (2024)
• Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
  di: Tamás Ágh, et al.
  Pubblicazione: (2025)
• Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
  di: Juliette A. van den Noort, et al.
  Pubblicazione: (2025)
• Medication adherence during the run‐in phase of clinical trials: A systematic review of methodological and reporting rigour
  di: Non Davies, et al.
  Pubblicazione: (2025)